Anteris Technologies prices $200 million public offering at $5.75 per share

Anteris Technologies Global Corp. (NASDAQ: AVR) announced the pricing of its public offering of 34,782,609 shares of common stock at $5.75 per share, according to a company statement. The medical device company expects gross proceeds of approximately $200 million before deducting underwriting discounts and expenses.

The offering is scheduled to close on January 22, 2026, subject to customary closing conditions. Anteris has granted underwriters a 30-day option to purchase up to an additional 5,217,391 shares at the public offering price.

Separately, Anteris entered into a stock purchase agreement with Medtronic plc for a private placement of up to $90 million in shares at the same price as the public offering. The private placement requires Medtronic to purchase between 16% and 19.99% of outstanding shares after the offering's completion.

The company plans to use proceeds to support its clinical strategy, including recruitment for the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe aortic stenosis and manufacturing expansion. Additional funds will support research and development for v2vmedtech, inc., working capital and general corporate purposes.

Barclays, Wells Fargo Securities and Cantor serve as joint book-running managers for the offering. Wells Fargo Securities acts as sole placement agent for the Medtronic private placement.

The shares are being offered under a shelf registration statement filed with the Securities and Exchange Commission that became effective on January 8, 2026. The Brisbane, Australia-based company develops medical devices for structural heart disease treatment.

You May Also Be Interested In

• Silence Therapeutics closes $201M public offering of ADSs
• bioAffinity Technologies closes $4M private placement offering
• VICI Properties closes $1.75B senior unsecured notes offering